Meghana V Trivedi

Associate Professor

University of Houston

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Meghana V Trivedi is an Associate Professor at the University of Houston, USA. Her research focuses on adherence patterns to endocrine therapies in breast cancer, including the effects of medications and interventions on patient outcomes. Recent publications highlight her work on the impact of socio-economic factors and race on treatment adherence in cancer patients, as well as the cost-effectiveness of various cancer therapies.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Xiaoyong Fu

Assistant Professor

Baylor College of Medicine

UNITED STATES

View details

CARMINE DE ANGELIS

Assistant Professor

University of Naples Federico II

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Meghana V Trivedi

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Group-Based Trajectory Model to Assess Adjuvant Endocrine Therapy Adherence Pattern in HR-Positive Breast Cancer: Results from Rio Grande Valley Patients

Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor–positive breast cancer

Group-Based Trajectory Modeling to Identify Patterns and Predictors of Adherence to Oral Endocrine Therapies in Underserved Population of Greater Houston Area

Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients

Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study

Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study

Interventions to improve oral endocrine therapy adherence in breast cancer patients

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer.

Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution.

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.

Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients

Collaborators (2)

Xiaoyong Fu

CARMINE DE ANGELIS

Make your next move.